PL2201100T3 - Wzmacnianie zdolności ludzkich komórek prezentujących antygen do stymulacji komórek T i ich zastosowanie w szczepieniu - Google Patents

Wzmacnianie zdolności ludzkich komórek prezentujących antygen do stymulacji komórek T i ich zastosowanie w szczepieniu

Info

Publication number
PL2201100T3
PL2201100T3 PL08804137.1T PL08804137T PL2201100T3 PL 2201100 T3 PL2201100 T3 PL 2201100T3 PL 08804137 T PL08804137 T PL 08804137T PL 2201100 T3 PL2201100 T3 PL 2201100T3
Authority
PL
Poland
Prior art keywords
cells
vaccination
enhancing
antigen presenting
human antigen
Prior art date
Application number
PL08804137.1T
Other languages
English (en)
Inventor
Kris Maria Magdalena Thielemans
Aude Bonehill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of PL2201100T3 publication Critical patent/PL2201100T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4245—Tyrosinase or tyrosinase related proteinases [TRP-1 or TRP-2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4268—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4272—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4273—Glycoprotein 100 [Gp100]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/52—CD40, CD40-ligand (CD154)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL08804137.1T 2007-09-14 2008-09-12 Wzmacnianie zdolności ludzkich komórek prezentujących antygen do stymulacji komórek T i ich zastosowanie w szczepieniu PL2201100T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP2007059732 2007-09-14

Publications (1)

Publication Number Publication Date
PL2201100T3 true PL2201100T3 (pl) 2016-10-31

Family

ID=38969592

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08804137.1T PL2201100T3 (pl) 2007-09-14 2008-09-12 Wzmacnianie zdolności ludzkich komórek prezentujących antygen do stymulacji komórek T i ich zastosowanie w szczepieniu

Country Status (7)

Country Link
US (1) US8476419B2 (pl)
DK (1) DK2201100T3 (pl)
ES (1) ES2573458T3 (pl)
HU (1) HUE029164T2 (pl)
PL (1) PL2201100T3 (pl)
PT (1) PT2201100E (pl)
WO (1) WO2009034172A1 (pl)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130108663A1 (en) * 2007-09-14 2013-05-02 Vrije Universiteit Brussel Enhancing the t-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and their use in vaccination
US9408909B2 (en) 2007-09-14 2016-08-09 Vrije Universiteit Brussel Enhancing the T-cell stimulatory capacity of human antigen presenting cells in vitro and in vivo and its use in vaccination
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
WO2010102278A1 (en) * 2009-03-06 2010-09-10 President And Fellows Of Harvard College Methods and compositions for the generation and maintenance of regulatory t cells
EP2494038B1 (en) * 2009-10-27 2019-06-26 Immunicum AB Method for proliferation of antigen-specific t cells
RU2447899C2 (ru) * 2010-05-27 2012-04-20 Михаил Валентинович Филатов Композиция для лечения гепатита с и способ лечения гепатита с
EP2696894B1 (en) 2011-04-13 2017-11-01 Immunicum AB Method for priming of t cells
DK2788021T3 (en) 2011-12-09 2017-04-10 Bavarian Nordic As POXVIRUS VECTOR FOR EXPRESSION OF BACTERIAL ANTIGENES CONNECTED TO TETANANOX INFRAGMENT C
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
US20150290306A1 (en) * 2012-10-29 2015-10-15 David E. Anderson Compositions and methods for diagnosis and treatment of malignant gliomas
CN104177499B (zh) * 2013-05-27 2019-01-08 上海雅科生物科技有限公司 一种嵌合抗原受体、编码基因、表达载体及其应用
EP4249065A3 (en) 2013-09-20 2023-11-15 Bristol-Myers Squibb Company Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors
ES2908268T3 (es) * 2013-11-12 2022-04-28 Univ Brussel Vrije Vector de transcripción de ARN y sus usos
US10603315B2 (en) 2013-11-26 2020-03-31 Technion Research And Development Foundation Limited Neuronal modulation
GB201501017D0 (en) 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
MD3626729T2 (ro) 2014-12-23 2021-12-31 Immatics Biotechnologies Gmbh Noi peptide și combinații de peptide pentru utilizare în imunoterapie împotriva carcinomului hepatocelular (HCC) și a altor cancere
IL309430A (en) * 2015-01-08 2024-02-01 Genmab As TNF receptor binding agonists
DK3623386T3 (da) * 2015-01-08 2022-07-04 BioNTech SE Agonistiske tnf-receptor-bindingsmidler
DK3173092T3 (da) 2015-04-22 2019-08-05 Curevac Ag Rna-holdig sammensætning til behandling af tumorsygdomme
JP7084304B2 (ja) * 2015-10-28 2022-06-14 ライフ テクノロジーズ エーエス 細胞表面シグナル及びシグナル比を変えることによる、異なるｔ細胞亜集団の選択的増殖の方法
KR101829978B1 (ko) * 2016-03-30 2018-02-20 가톨릭대학교 산학협력단 Ｂ 세포 백신 및 이의 용도
WO2017201350A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Polynucleotides encoding interleukin-12 (il12) and uses thereof
MA45037A (fr) 2016-05-18 2019-03-27 Modernatx Inc Polythérapie à base d'arnm pour le traitement du cancer
CN110402145A (zh) * 2016-10-26 2019-11-01 莫得纳特斯公司 用于增强免疫应答的信使核糖核酸及其使用方法
US11422127B2 (en) * 2016-12-07 2022-08-23 Albany Medical College Ex vivo antigen and adjuvant pulsed peripheral blood mononuclear cells as a screening platform for candidate novel vaccines and candidate antigens
US20190351039A1 (en) 2017-02-01 2019-11-21 Modernatx, Inc. Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides
AU2018229278A1 (en) 2017-02-28 2019-10-17 Sanofi Therapeutic RNA
EP3625246A1 (en) 2017-05-18 2020-03-25 ModernaTX, Inc. Polynucleotides encoding tethered interleukin-12 (il12) polypeptides and uses thereof
AU2018277824A1 (en) 2017-05-30 2019-10-17 Bristol-Myers Squibb Company Treatment of LAG-3 positive tumors
KR20240155979A (ko) 2017-05-30 2024-10-29 브리스톨-마이어스 스큅 컴퍼니 항-lag-3 항체 또는 항-lag-3 항체 및 항-pd-1 또는 항-pd-l1 항체를 포함하는 조성물
CN116333131A (zh) 2017-08-04 2023-06-27 健玛保 与pd-l1和cd137结合的结合剂及其用途
CA3104833A1 (en) 2018-07-16 2020-01-23 Dcprime B.V. A combination product for use in tumor vaccination.
WO2020072833A1 (en) * 2018-10-04 2020-04-09 Sqz Biotechnologies Company Intracellular delivery of biomolecules to enhance antigen presenting cell function
AU2020204781A1 (en) * 2019-01-04 2021-08-12 Etherna Immunotherapies Nv mRNA vaccine
CA3133410A1 (en) 2019-04-25 2020-10-29 Dcprime B.V. Methods of tumor vaccination
JP7650001B2 (ja) * 2019-04-26 2025-03-24 イーザアールエヌーエー イムノセラピーズ エンヴェー ｍＲＮＡ製剤
CN110151999A (zh) * 2019-05-22 2019-08-23 中国人民解放军第四军医大学 用于抑制恶性黑色素瘤进展的靶向药物
IL296556A (en) * 2020-03-16 2022-11-01 Univ Brussel Vrije A mixture of mrna to increase the potency of dendritic cells
WO2021191870A1 (en) 2020-03-27 2021-09-30 Dcprime B.V. Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
JP2023531537A (ja) 2020-06-30 2023-07-24 メンドゥス・ベスローテン・フェンノートシャップ 卵巣癌ワクチンでの白血病由来細胞の使用
AU2022211682A1 (en) 2021-01-22 2023-08-03 Mendus B.V. Methods of tumor vaccination
CN114317435B (zh) * 2021-12-30 2024-02-27 杭州芯递力生物科技有限公司 一种获得抗原特异性t细胞的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6734014B1 (en) * 1996-02-08 2004-05-11 The United States Of America As Represented By The Department Of Health And Human Services Methods and compositions for transforming dendritic cells and activating T cells
US6969609B1 (en) * 1998-12-09 2005-11-29 The United States Of America As Represented By The Department Of Health And Human Serivces Recombinant vector expressing multiple costimulatory molecules and uses thereof
PT1651755E (pt) 2003-08-04 2011-01-18 Imba Inst Molekulare Biotech Método para imunoterapia de tumores
EP2295588B1 (en) * 2004-05-27 2018-03-07 The Trustees Of The University Of Pennsylvania Novel artificial antigen presenting cells and uses thefor
DK1809737T3 (da) 2004-10-07 2011-03-07 Argos Therapeutics Inc Sammensætninger med modne dendritceller og fremgangsmåder til dyrkning af disse
EP1806395A1 (en) 2006-01-06 2007-07-11 Stichting Sanquin Bloedvoorziening Maturation of dendritic cells

Also Published As

Publication number Publication date
US20100215674A1 (en) 2010-08-26
WO2009034172A1 (en) 2009-03-19
US8476419B2 (en) 2013-07-02
ES2573458T3 (es) 2016-06-08
PT2201100E (pt) 2016-06-03
HUE029164T2 (hu) 2017-02-28
DK2201100T3 (en) 2016-05-30

Similar Documents

Publication Publication Date Title
PL2201100T3 (pl) Wzmacnianie zdolności ludzkich komórek prezentujących antygen do stymulacji komórek T i ich zastosowanie w szczepieniu
IL223376A0 (en) Preparation of inactivated artificial antigen presenting cells and their use in cell therapies
PL2700708T3 (pl) Zwiększanie zdolności limfocytów T do stymulacji ludzkiego antygenu prezentującego komórki in vitro oraz in vivo i jego zastosowanie w szczepieniu
GB2465291B (en) Human pluripotent stem cells and their medical use
GB0605702D0 (en) Materials and methods for immune cell stimulation
PL2287195T3 (pl) Przeciwciała pan-kir2dl receptora nk i ich zastosowanie w diagnostyce i terapii
PL2117718T3 (pl) Nowe kolektory ditiokarbaminianów i ich zastosowanie we wzbogacaniu złóż rudy minerału
PL2282758T3 (pl) Przeciwciała i szczepionki do zastosowania w terapeutycznych i diagnostycznych sposobach dla zaburzeń związanych z alfa-synukleiną
PT2162118T (pt) Microesferas porosas e sua utilização em terapia
GB0700133D0 (en) Human cytomegalovirus neutralising antibodies and use thereof
RS56230B1 (sr) Analitički postupci i čipovi za upotrebu u identifikaciji agenasa koji indukuju senzibilizaciju humane kože
PT2291394T (pt) Proteínas de fusão e seus usos no diagnóstico e tratamento de leishmaniose
IL201034A0 (en) Novel human anti-r7v antibodies and uses thereof
PL2055718T3 (pl) Ukierunkowywanie i śledzenie antygenów w żywych komórkach
IL205780A0 (en) Fviii peptides and their use in tolerising haemophiliacs
ZA200902419B (en) Anti-notch3 agonist antibodies and their use in the treatment of notch3-related diseases
IL208579A0 (en) Methods and use of inducing a poptosis in cancer cells
IL199618A0 (en) Novel antibodies and their use in diagnostic methods
PT2465523E (pt) Péptidos derivados de fviii e seu uso na tolerização de hemofílicos
EP1802740A4 (en) TRANSGENIC STRAINS OF TRICHODERMA AND THEIR USE IN BIOLOGICAL CONTROL
EP2638167A4 (en) DOMINANT NEGATIVE MUTANT KIP PROTEINS IN ZEA-MAIZE AND METHOD FOR THEIR USE
GB0505908D0 (en) Antibodies and their use in therapy
HK1170538A (en) Novel antibodies and their uses in therapeutic and diagnostic methods
GB0424871D0 (en) Antibodies and their use in therapy
GB201001170D0 (en) Novel peptides and their use in therepy and diagnosis